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Mice harboring the waved-1 {wa-1) and waved-2 {wa-2) mutations exhibit skin and eye abnormalities that are 
strikingly similar to those of TGF-a-deficient mice, and wa-1 and TGF-a were recently shown to be allelic. 
Because the wa-2 mutation was mapped previously to the vicinity of the EGF/TGF-a receptor (EGFR) gene on 
mouse chromosome 11, we hypothesized that the wa-2 phenotype might result from a defect in either the 
expression or activity of EGFR, or both. In the present report, we show that EGFR mRNA and protein of 
normal size are expressed in wa-2 liver and skin at levels that are comparable to those in the corresponding 
normal tissues, and that the ability of wa-2 EGFR to bind ligand is unaltered. However, ligand-dependent 
autophosphorylation of wa-2 EGFR is diminished 5- to 10-fold in vitro, and the ability of wa-2 EGFR to 
phosphorylate an exogenous substrate is reduced by >90% compared with that of the control receptor. 
EGF-induced tyrosine phosphorylation, including that of EGFR itself, is also diminished in skin, particularly 
at lower doses of exogenous EGF. To establish the nature of the wa-2 mutation, we determined the nucleotide 
sequence of the coding region of normal and wa-2 murine EGFR cDNAs. A comparison of these sequences 
revealed a single-nucleotide transversion resulting in the substitution of a glycine for a conserved valine 
residue near the amino terminus of the tyrosine kinase domain. The importance of this mutation was 
confirmed by showing that its introduction into an otherwise normal EGFR markedly reduced the receptor's 
tyrosine kinase activity in transfected Chinese hamster ovary cells. Finally, in situ hybridization analysis 
demonstrated expression of EGFR predominantly in the outer root sheath of active hair follicles in neonatal 
mice. As we previously localized TGF-a mRNA to the inner root sheath, this pattern of EGFR expression is 
consistent with the effect of the wa-2 mutation on hair structure, and together with our previous 
characterization of TGF-a-deficient mice, reveals a critical role for signaling by this ligand/receptor system in 
skin. 
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A range of cellular activities, including proliferation, mi-
gration, and differentiation, are controlled by signal 
transduction systems that are activated by the binding of 
polypeptide growth factors to cell-surface receptors. The 
majority of these receptors consist of an extracellular 
ligand-binding domain linked to a cytoplasmic sequence 
with intrinsic protein kinase activity that is specific for 
tyrosine residues (for review, see Ullrich and Schless-
inger 1990; also see Carpenter and Wahl 1990). One of 
the better characterized tyrosine kinase receptors is the 
epidermal growth factor receptor (EGFR), a 170-kD inte-
gral membrane glycoprotein. The extracellular domain 
of EGFR includes two cysteine-rich regions. The intra-
^Conesponding author. 
cellular domain comprises a juxtamembrane region con-
taining sites for threonine/serine phosphorylation that 
may be required for modulation of EGFR activity by 
other signaling systems, a tyrosine kinase domain ho-
mologous to that of other receptor and nonreceptor ty-
rosine kinases, and a carboxy-terminal region that con-
tains regulatory sites for tyrosine autophosphorylation. 
EGFR binds, and is activated by, a family of polypeptide 
ligands that is named for the first discovered member, 
epidermal growth factor (EGF) (Cohen 1962). This ex-
panding family includes transforming growth factor-a 
(TGF-a) (Marquardt et al. 1984), amphiregulin (Shoyab et 
al. 1989), heparin-binding EGF (HB-EGF) (Higashiyama 
et al. 1991), and betacellulin (Sasada et al. 1993; Shing et 
al. 1993), and the amphiregulin-related Schwaimoma-de-
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rived growth factor (SDGF) may be yet another distinct 
member (Kimura et al. 1990). Binding of these various 
ligands to EGFR in cell culture typically leads to en-
hanced protein phosphorylation at tyrosine residues, ac-
tivation of transport systems, and in some cell lines, 
stimulation of phosphoinositide turnover. These early 
responses are typically followed several hours later by 
increased synthesis of specific macromolecules (both 
RNA and protein), and within 12-48 hr, stimulation of 
DNA synthesis. Expression of EGFR is widespread, and 
in rodents, EGFR mRNA, or protein, are detected in 
most adult tissues with particularly high levels in liver. 
EGFR-binding activity is also present in certain fetal tis-
sues (Adamson 1990; Wiley et al. 1992). Despite a wealth 
of cell culture data, physiological roles for the EGFR sig-
naling system have not been well defined. Furthermore, 
little is known regarding possible distinctions between 
physiological responses evoked by different members of 
the EGF ligand family. To begin to address these issues, 
we recently used gene targeting in embryonic stem (ES) 
cells to derive a line of mice that is homozygous for a 
disrupted TGF-a gene and, hence, cannot express fimc-
tional TGF-a protein (Luetteke et al. 1993). These mice 
are healthy and fertile but are distinguished by pro-
nounced waviness of whiskers and fur. Individual coat 
hairs are bent and kinked, and contain regions of irreg-
ular septulation and caliber. These hairshaft defects are 
accompanied by aberrant curvature, disorientation, and 
misalignment of active hair follicles. Additionally, ho-
mozygous and, to a lesser extent, heterozygous TGF-a 
mice display eye anomalies of variable incidence and se-
verity. The development of abnormal skin architecture, 
wavy hair, and eye problems in response to loss of TGF-a 
was simultaneously described by Mann et al. (1993), who 
used a different targeting strategy to inactivate the 
TGF-a gene. 
A number of recessive mouse mutations affecting coat 
texture have been described previously (Trigg 1972; Lyon 
and Searle 1989). Two of these, waved-1 [wa-l] and 
waved-2 {wa-2], show hair and eye alterations that are 
strikingly similar to those of the TGF-a-deficient mice 
(Crew 1933; Keeler 1935; Butler and Robertson 1953; 
Bennett and Gresham 1956; Trigg 1972). Because wa-l 
and TGF-a map to a similar region on mouse chromo-
some 6 (Fowler et al. 1993; Barrow et al. 1994; N.G. 
Copeland and N.A. Jenkins, unpubL), the possibility that 
wa-l and TGF-a are related was examined previously. 
Crosses between TGF-a-targeted and wa-l mice con-
firmed that the two loci are allelic (Luetteke et al. 1993; 
Mann et al. 1993), and expression of a normal-sized 
TGF-a mRNA was shown to be significantly reduced in 
several tissues relative to that in control mice (Luetteke 
et al. 1993). Because we localized TGF-a transcripts to 
the hair follicles of normal mice, these various results 
confirm a critical role for this particular EGFR ligand in 
skin. On the other hand, wa-2, a cell autonomous mu-
tation (McLaren and Bowman 1969), maps to the vicinity 
of the EGFR gene on mouse chromosome 11 (Lyon and 
Searle 1989). Hence, we sought to determine whether the 
wa-2 phenotype might result from a defect in either the 
expression or activity of EGFR. In the present report, we 
show that the wa-2 EGFR contains a point mutation 
within its tyrosine kinase domain that greatly dimin-
ishes its activity in vitro and leads to reduced EGF-de-
pendent tyrosine phosphorylation in skin, particularly at 
lower doses of exogenous EGF. Together with our dem-
onstrations that EGFR and TGF-a transcripts are local-
ized to the outer and inner root sheaths, respectively, 
these findings define a physiological context in which 
interaction between EGFR and one of its ligands is crit-
ical. Our results also indicate that a mutation in a sig-
naling protein, in this case EGFR, can have conse-
quences that are tissue specific. 
Results 
EGFR transcripts are localized to the outer root 
sheath of hair follicles 
To further investigate the role of TGF-a/EGFR interac-
tions in hair follicle function and morphology, we per-
formed in situ hybridization analyses of sections of nor-
mal backskin and snout in the active hair growth phase 
(anagen). An antisense RNA, corresponding to the intra-
cellular ligand-binding domain of mouse EGFR, specifi-
cally detected prominent expression of EGFR transcripts 
in the outer root sheath of both vibrissal (Fig. la, arrow-
heads) and pelage (Fig. Id, arrow) hair follicles of mice at 
7 days of age. This pattern of expression, which was sim-
ilarly observed with an antisense probe derived from 
cDNA sequences encoding the extracellular domain of 
the receptor, is distinguished from that of TGF-a tran-
scripts, as they were primarily localized to the adjoining 
inner root sheath (Fig. lb, arrowheads; see also Luetteke 
et al. 1993). These data confirm that ligand and receptor 
are positioned appropriately to regulate interactions be-
tween inner and outer root sheaths that are thought to be 
important for hair growth (Straile 1962j Hardy 1992). In-
terestingly, EGFR transcripts were observed along the 
entire length of the outer root sheath from the prolifer-
ative bulb to the basal epidermis (Fig. Id; data not 
shown), whereas TGF-a transcripts were confined longi-
tudinally to a limited region of irmer root sheath above 
the bulb (Luetteke et al. 1993). This could be consistent 
with differential expression of other EGFR ligands. Fi-
nally, we note that while Nanney et al. (1992) immuno-
localized EGFR and PLC'-yl primarily to the basal layer 
of normal skin, they did not examine expression of these 
proteins in active hair follicles. 
Expression of EGFR is unaltered in wa-2 mice 
To determine whether the wa-2 phenotype results from 
reduced expression of either EGFR mRNA or protein, we 
performed Northern and Western blot analyses. As 
shown in Figure 2A, normal-sized EGFR transcripts of 
~9.6, 6.5, 5.0, and 2.7 kb were expressed in livers of adult 
wa-2 homozygotes and heterozygotes at levels compara-
ble to those in adult B6C3 mice. Whereas only the 6.5-
and 5.0-kb mRNAs were detected in neonatal skin, these 
400 GENES & DEVELOPMENT 
 Cold Spring Harbor Laboratory Press on February 2, 2021 - Published by genesdev.cshlp.orgDownloaded from 
wa-2 encodes a defective EGF receptor 
Figure 1. In situ hybridization detection of EGFR and TGF-a transcripts in normal hair follicles, {a) Cross section of a whisker follicle 
in the snout of a 7-day-old pup hybridized to an antisense cRNA probe corresponding to the extracellular domain of mouse EGFR. 
Specific hybridization (arrowheads) is prominent in the outer root sheath, [b] Comparable section hybridized to an antisense cRNA 
probe for mouse TGF-a. Hybridization is most intense next to one side of the vibrissal hairshaft, in the irmer root sheath, (c) Snout 
section adjacent to that in a, hybridized to the sense cRNA of the mouse EGFR cDNA. [d] Hybridization of the antisense EGFR cRNA 
to a section of backskin from a 7-day-old mouse showing expression in the hair bulbs (arrowheads), as well as in the outer root sheath 
along the hairshaft (arrow). All magnifications are 400x. (ors) Outer root sheath; (irs) inner root sheath; (h) hairshaft. 
were also expressed at similar levels in wa-2 homozy-
gous and wa-2 heterozygous mice. Moreover, compara-
ble levels of EGFR protein were detected by an anti-rat 
EGFR antibody in microsomal and plasma membrane 
fractions prepared from livers of control and wa-2 mice, 
and the wa-2 EGFR migrated with an apparent size (170 
kD) identical to that of the normal protein (Fig. 2B). 
These results distinguish the basis of the wa-2 pheno-
type from that of wa-1, which results from reduced ex-
pression of TGF-a mRNA and protein (Luetteke et al. 
1993), and they also indicate that wa-2 EGFR does not 
contain significant sequence deletions. 
The tyrosine kinase of the WSL-1 EGFR shows 
diminished activity in vitro 
To examine its functional competency, we compared the 
autophosphorylation of normal and wa-2 EGFRs in liver 
membranes in response to increasing amounts of EGF. 
As expected, we observed a ligand-dependent increase in 
^^P incorporation into the 170-kD EGFR protein in con-
trol liver membranes (Fig. 3A). Because this radiolabeling 
was resistant to alkali treatment, it is presumed to rep-
resent tyrosine autophosphorylation of the receptor. In 
contrast, EGF-dependent phosphorylation of the wa-2 
EGFR from homozygous liver membranes was markedly 
reduced even at the highest dose of EGF (Fig. 3A), and 
TGF-a-induced autophosphorylation of the wa-2 EGFR 
was also markedly decreased (data not shown). Because 
the preceding autophosphorylation experiments were 
performed at 0°C, we considered the possibility that the 
wa-2 defect might be temperature sensitive. However, 
autophosphorylations carried out at 37°C showed an 
even greater difference between the activities of the con-
trol and wa-2 receptors (Fig. 3A), although autophospho-
rylation of both receptor forms was essentially ligand-
independent at this higher temperature. Densitometric 
analyses of the autoradiographs shown in Figure 3 re-
vealed autophosphorylation of the wa-2 EGFR at 0°C to 
be reduced five- and sixfold compared with the control 
receptor at 600 and 2000 ng/ml of EGF, respectively. In 
contrast, the comparative reductions at 37°C were 16-
and 25-fold, respectively. Finally, we note the intense 
phosphorylation of a polypeptide of —42 kD that was 
observed only with control membranes incubated at 
37°C (Fig. 3A). Though it is similar in size to mitogen-
activated protein kinase (MAP kinase) (Campos-Gonza-
lez and Glenney 1992), the 42-kD protein was not rec-
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Figure 2. Expression of EGFR mRNA and protein in normal 
and wa-2 mice. [A] Northern blot of total RNAs (15 jig) isolated 
from the livers of adult male B6C3 ( + / + ) and age-matched 
wa-2 heterozygous (wa-2/ + ) and homozygous (wa-2/wa-2) 
mice, and from the backskin of 10-day-old heterozygous and 
homozygous wa-2 littermates. Blots were probed with nick-
translated, full-length murine EGFR cDNA. [B] Westem blot of 
proteins from microsomal and plasma membranes isolated from 
the livers of adult normal and wa-2 homozygous mice, probed 
with rabbit antiserum directed against the carboxy-terminal re-
gion of rat EGFR. 
ognized by an anti-IVlAP-kinase antibody (data not 
shown) and its identity is presently unknown. 
EGFR has been shown previously to be activated in the 
absence of ligand by solvents, detergents, and antibodies 
(Rubin and Earp 1983; Schreiber et al. 1983; Yarden and 
Schlessinger 1987). As shown in Figure 3B, treatment of 
nonsolubilized membranes with dimethylsulfoxide 
(DMSO), or solubilized membranes with antiserum di-
rected against the EGFR extracellular domain, induced a 
concentration-dependent autophosphorylation of the re-
ceptor in control, but not wa-2, samples. These results 
imply that the wa-2 defect is not merely the result of 
impaired binding of ligand to the wa-2 receptor. Mea-
surements of ^^^I-labeled EGF binding to hepatic micro-
somal membranes from wa-2 mice showed it to be sim-
ilar to that observed with B6C3 membranes. The com-
petition binding curves shown in Figure 4 fit a single site 
model with apparent dissociation constants estimated at 
0.55 and 1.05 nM for normal and wa-2 EGFR, respec-
tively. These are similar to the previously reported value 
of 0.67 nm for rat liver membranes (Friedenberg et al. 
1986). 
To assess the activity of the wa-2 EGFR tyrosine ki-
nase toward exogenous substrates, we examined its abil-
ity to phosphorylate synthetic peptide polymers contain-
ing tyrosine (Zick et al. 1985). This particular assay was 
chosen, as phosphorylation of these polymers is limited 
to tyrosine residues and is independent of src homology 
2 (SH2) domain binding, which could be compromised 
with an underphosphorylated mutant EGFR. Equivalent 
amoimts of protein were immunoprecipitated from sol-
ubilized wa-2 homozygous or control wild-type micro-
somal membranes with an antisera (1382) against the 
extracellular domain of rat EGFR. As shown in Figure 
3B, binding of this antibody activates the receptor, and in 
other experiments we found that pretreatment with EGF 
did not enhance the level of receptor kinase activity over 
that observed in response to antibody binding alone (data 
not shown). Immunoprecipitates were incubated with 
[7-^^P]ATP and poly-glutamic acid (poly-Glu), poly-glu-
tamate/tyrosine (4:1) (poly-Glu/Tyr), or poly-glutamate/ 
alanine/tyrosine (poly-Glu/Ala/Tyr) as substrates. As 
shown in Figure 5, normal EGFR catalyzed a 95- and 
147-fold increase in the incorporation of ^^P into poly-
Glu/Tyr and poly-Glu/Ala/Tyr, respectively, relative to 
poly-Glu. In contrast, the corresponding increase pro-
duced by the wa-2 EGFR was less than threefold, and 
was only slightly above that obtained with the preim-
mune precipitates from both genotypes. SDS-PAGE of 
the phosphorylated polymers revealed an intense smear 
of ^^P incorporation only in the case of poly-Glu/Tyr 
incubated with the control EGFR. Taken together, these 
results confirm that tyrosine phosphorylation of both 
the wa-2 EGFR itself, as well as of exogenous substrates, 
is greatly reduced in vitro. 
wa-2 EGFR activity is also impaired in vivo 
Administration of EGF to newborn mice has been shown 
to rapidly induce tyrosine phosphorylation of EGFR and 
other proteins in multiple tissues (Donaldson and Cohen 
1992). Hence, we used this approach to examine the ac-
tivity of the wa-2 EGFR tyrosine kinase in vivo. For 
these analyses, we used 1-week-old pups because the 
wa-2 phenotype is most evident during anagen of the 
first hair cycle. Because we were unable to distinguish 
(either by phenotype or genotype) heterozygous and 
wild-type pups, we mated wa-2 homozygous males to 
wa-2 heterozygous females to generate equal numbers of 
wa-2 homozygous and heterozygous (control) litter-
mates. At 1 week of age, homozygous mutant and het-
erozygous control littermates were injected subcutane-
ously with either PBS alone or PBS containing a pharma-
cological dose of EGF (10 ixg/g body weight). Ten 
minutes later, the pups were sacrificed, and liver, skin, 
and kidney homogenized in a buffer containing detergent 
and protease and phosphatase inhibitors. Equivalent 
amounts of tissue protein were then resolved by SDS-
PAGE, and immunoblots probed with either anti-phos-
photyrosine antibody (PY-20) or anti-rat EGFR antise-
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Figure 3. Autophosphorylation of the 
EGFR in control and wa-2 liver mem-
branes. [A] Dose response of protein (50 
\x.g] from control ( + / + ) or wa-2 ( - / - ) 
liver membranes to EGF (0-2000 ng/ml), 
with [-/-̂ ^P]ATP incubations at 0°C (left] 
or 37°C [right]. Prior to autoradiography, 
SDS-PAGE gels were treated with 1 M 
KOH for 2 hr at 55°C to preferentially re-
move serine and threonine phosphoryla-
tion. [B] Ligand-independent autophospho-
rylation of normal and wa-2 EGFR. Mem-
branes (50 (xg) were preincubated for 1 hr 
on ice with or without EGF (2 |xg/ml), or 
with increasing concentrations of DMSO, 
and phosphorylation initiated with 
[7-^^P]ATP. Alternatively, membrane 
samples were first solubilized in 1% Tri-
ton X-100 on ice, then diluted and incu-
bated for 1 hr at room temperature in the 
absence or presence of EGF, or in several 
dilutions of antiserum against the extra-
cellular domain of the EGFR prior to the 
phosphorylation reaction at 0°C. 
rum. As reported previously for normal mice (Donaldson 
and Cohen 1992), injection of EGF in the heterozygous 
controls led to enhanced tyrosine phosphorylation of 
both EGFR and a protein of —55 kD in liver, skin, and 
kidney (Fig. 6A). Tyrosine phosphorylation of 120- and 
35-kD species v̂ âs also increased, particularly in skin 
and kidney. Surprisingly, tyrosine phosphorylation of 
these same proteins (including EGFR itself) was signifi-
cantly stimulated in corresponding tissues from wa-2 
homozygous pups, though phosphorylation of both 
EGFR and pi20 was consistently (albeit slightly) reduced 
in skin (Fig. 6A). 
1 00 
EGF Concentration (nM) 
Figure 4. Comparison of EGF binding in 
control (-(- / -I-) and wa-2 ( - / - ) liver mem-
branes. Membrane suspensions (40 fig pro-
tein in 200 \d] were incubated for 4 hr at 
4°C with 0.5 nM ^^^i-iabeled EGF and EGF 
(0-20 nM), and bound ligand recovered by 
vacuum filtration and washing. Data 
points were derived from the mean of three 
values, with standard errors within 10% of 
the mean. (Open symbols) controls; (closed 
symbols) wa-2. Nonspecific binding, mea-
sured in the presence of 2 ixM EGF, was 
<10% of total binding. Maximal specific 
binding was 2237 cpm for control and 2838 
cpm for wa-2 samples. 
GENES & DEVELOPMENT 403 
 Cold Spring Harbor Laboratory Press on February 2, 2021 - Published by genesdev.cshlp.orgDownloaded from 




EGFR preimmune EGFR 
control wa-2 
Figure 5. Tyrosine kinase assay of control ( + / + ) and v7a-2 
( - / - ) EGFR. Liver microsomal membranes (400 |xg protein per 
reaction) were solubilized and immunoprecipitated with preim-
mime rabbit serum or antiserum recognizing the EGFR extra-
cellular domain. Washed irmnune complexes were then incu-
bated for 15 min at 25°C with 5.0 |xCi [7-^^P]ATP and 2 mg/ml 
of either poly-Glu (E) or poly-Glu/Tyr (EY) or poly-Glu/Ala/ 
Tyr) (EAY). Reactions were centrifuged to pellet the immune 
complexes and eliminate the backgroimd contribution of EGFR 
autophosphorylation. Aliquots of the supernatant were spotted 
onto filter papers that were washed extensively and subjected to 
Cherenkov covmting. Bars, mean values from triplicate assays, 
with standard errors within 10% of the mean. 
Because the latter experiment was performed with a 
particularly high dose of EGF, it was repeated with lower 
doses of EGF (ranging from 0.25 to 2 jig/g body weight). 
As shown in Figure 6B, phosphorylation of EGFR, as well 
as of p i20 and p55, was dose dependent in skin from both 
control and wa-2 homozygous mice, but a comparison of 
individual doses showed the levels of tyrosine phospho-
rylation to be consistently lower in wa-2 homozygous 
tissues versus control heterozygous tissues. Although 
they were also observed in liver (data not shown), differ-
ences between the acrivities of the control and wa-2 
EGFRs were most evident in skin at doses of EGF that 
were minimally sufficient to yield significant phospho-
rylation relative to background levels (e.g., 1 |xg/g body 
weight). Densitometric analysis of the results shown in 
Fig. 6B revealed an approximately sevenfold decrease in 
tyrosine phosphorylation of the p i20 substrate in wa-2 
homozygous versus control homogenates at a dose of 1 
p-g/g EGF. Because other phosphoproteins migrated in 
the vicinity of EGFR, its phosphorylation was examined 
further by inomunoprecipitation with EGFR antiserum 
prior to immimoblotting (Fig. 6C). Compared with con-
trol, EGFR phosphorylation induced by 1 |xg/g of EGF 
was reduced about fourfold in wa-2 homozygous skin. 
The differences in tyrosine phosphorylation in the wa-2 
tissues were not attributable to differential receptor con-
tent, as Western blots of the same homogenates probed 
with anti-rat EGFR antibody confirmed comparable lev-
els of receptor protein (Figure 6A-C, bottom). Finally, 
note that (as described above) to compare age-matched 
littermates of known genotypes, these studies were car-
ried out with wa-2 heterozygotes as controls. Hence, the 
difference between tyrosine phosphorylation mediated 
by the normal and wa-2 EGFRs in vivo is potentially 
imderestimated by these experiments. 
To further evaluate the physiological significance of 
the reduced EGFR kinase activity in vivo, we injected 
one litter of 10 newborn mice daily for 2 weeks with 1 
fjig/g of EGF (Cohen 1962; Tarn 1985). Compared with 
PBS injection (n = 2 pups of each genotype), EGF simi-
larly accelerated eyelid opening and incisor eruption by 
2-3 days in both heterozygous (n = 3 pups) and homozy-
gous (i2 = 3 pups) wa-2 littermates. Interestingly, the ad-
ministration of EGF to wa-2 homozygous mice did not 
override the wavy hair phenotype. 
The wa-2 EGVR is mutated within the tyrosine kinase 
domain 
Collectively, the previous findings are consistent with a 
mutation in the wa-2 EGFR-coding region. To identify 
the mutation, overlapping cDNAs corresponding to the 
extracellular domain and the transmembrane/cytoplas-
mic regions were generated by reverse transcription and 
polymerase chain reaction (RT-PCR) amplification of to-
tal RNAs from the livers of normal B6C3 and wa-2 ho-
mozygous mice. Resulting cDNAs were cloned and their 
nucleotide sequences determined by automated dideoxy 
sequencing. Discrepancies between the various clones 
were then investigated further by manual sequencing of 
selected regions. A total of four clones (two each, wild-
type and wa-2) corresponding to the extracellular do-
main were sequenced in the forward direction. The com-
plete sequences of eight clones (four each, wild-type and 
wa-2) corresponding to the transmembrane/cytoplasmic 
domain were determined. For each genotype, half of the 
latter clones were sequenced in the forward direction 
and half in the reverse direction. In a comparison of the 
individual sequences corresponding to the extracellular 
domain, only three different discrepancies were noted, 
and each appeared in only one of four clones examined. 
Similarly, a comparison of the eight transmembrane/cy-
toplasmic domain clones revealed a total of 10 different 
discrepancies, none of which appeared in more than one 
clone. These various discrepancies (most of which were 
silent) were therefore judged to be PCR-generated arti-
facts. 
The complete consensus nucleotide sequence and pre-
dicted amino acid sequence of the normal murine EGFR 
cDNA is presented in Figure 7A. Relative to human 
EGFR, the mouse protein contains a 2 amino-acid-insert 
immediately preceding the transmembrane domain and 
lacks 2 amino acids in the carboxy-terminal region. 
Thus, its overall length (1186 amino acids) is identical to 
that of the human receptor. The amino acid sequence of 
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Figure 6. EGF-induced tyrosine phosphorylation in vivo. (A) Tyrosine phosphory-
lation in neonatal tissues expressing EGFR. One-week-old wa-2 heterozygous con-
trol and homozygous mutant littermates were administered PBS (-) or EGF in PBS 
(-I-) at 10 |xg/g of body weight. Ten minutes later, pups were sacrificed and indicated 
tissues removed and homogenized in buffer containing 1% Triton X-100 and pro-
tease and phosphatase inhibitors. Equivalent samples (200 |xg protein) were sub-
jected to SDS-PAGE and Western blotting with anti-phosphotyrosine antibody (top] 
or EGFR antiserum [bottom]. [B] EGF dose response in skin. Experiment performed 
as in A, but with lower doses of EGF as indicated. (C) EGFR autophosphorylation in 
neonatal skin. Skin homogenates (500 |xg protein) from the experiment in B were 
immunoprecipitated with EGFR antiserum, and then subjected to parallel Western 
blotting with anti-phosphotyrosine antibody [top] or EGFR antiserum [bottom]. 
control wa-2 
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the extracellular portion predicted from this sequence is 
identical to that determined previously for EGFR from a 
different mouse strain (Avivi et al. 1991) and is 87% 
homologous with human EGFR. The cytoplasmic do-
main, which has not been reported previously for ro-
dents, is 94% homologous with the human EGFR (Ull-
rich et al. 1984), with almost complete conservation of 
the tyrosine kinase domain as well as sites of tyrosine 
and serine/threonine phosphorylation. Overall, the 
mouse EGFR sequence is 95% homologous with that of 
rat receptor (T. Dawson and H.S. Earp, pers. comm.). 
Significantly, comparison of the wa-2 EGFR cDNA se-
quence with the wild-type consensus sequence shown in 
Figure 7A revealed only a single consistent nucleotide 
difference involving the replacement of a thymidine 
with a guanosine (Figure 7B) in the tyrosine kinase do-
main. This transversion, which was observed with all 
four of the wa-2 clones, and not observed with any of the 
wild-type clones, would result in the substitution of a 
glycine for a valine (residue 743) in the third subdomain 
(as defined by Hanks et al. 1988) of the protein kinase 
sequence. Interestingly, this particular valine is con-
served between human, mouse, and rat EGFRs, as well as 
in Her2/ErbB2/Neu (Table 1). Moreover, it is either con-
served or conservatively replaced by an isoleucine or leu-
cine in a multitude of receptor arid nonreceptor tyrosine 
kinases (including the EGFR-related Her4/ErbB4; Plow-
man et al. 1993), as well as in a majority of known 
serine/threonine kinases (Hanks et al. 1988). Although it 
is replaced by alanine in the EGFR-related Her3/ErbB3, 
subdomain III of this latter protein shows little related-
ness to the comparable region of other EGFR-related pro-
teins and, in particular, lacks the glutamic acid residue 
that is otherwise conserved in both tyrosine and serine/ 
threonine protein kinases (see Table 1; Plowman et al. 
1990). 
Introduction of the wa-2 mutation impairs 
normal receptor kinase activity 
The implicated valine residue at position 743 is encoded 
within a 768 bp £coRI fragment. This fragment is pre-
served in a full-length rat EGFR cDNA with 99% (254/ 
256) conservation (relative to mouse) of the encoded 
amino acids. To confirm the importance of the wa-2 va-
line 743 substitution, we replaced this portion of the rat 
EGFR cDNA with the corresponding £coRI cassettes de-
rived from wild-type and wa-2 mouse cDNAs. We chose 
this particular strategy because our PCR-generated 
mouse cDNAs could not be readily assembled into full-
length sequences, and most contained random muta-
tions as described above. The two modified rat EGFR 
cDNAs were introduced separately into the plasmid 
pcDNA3 (Invitrogen) under the control of cytomegalovi-
rus (CMV) promoter, and the presence of the appropriate 
mouse cassette (wild-type vs. wa-2] confirmed by nucle-
otide sequence analysis. 
To assess the impact of the wa-2 mutation, subconflu-
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ctgtctcggat taatcccggagagccagagccaaoctctccoggtcagagATXX:GACCCTCAGGGACCGCGAGAACCACACTGCTGGTGTTGCTGACCGCGCTCTCCGCCGCAGGTGGGGCGTTGGA(XAAAAGAAAGTC^ 
M R P S G T A R T T L L V L L T A L C A A G G A L E E K K V C Q G T 
- 2 4 - 2 0 - 1 0 1 10 
CAAGTAACAGGCTCACCCAACTGGGCACTTTTGAAGACCACTn'CTGAGCCTGCAGAGGATGTACAACAACTGTGAAGTGGTCXrTTGGGAACTTGGAAATrACCTATGTGCAAA 
S N R L T Q L G T F E D H F L S L Q R M Y N N C E V V L G N L E I T Y V Q R N Y D L S F L K T I Q E 
20 3 0 40 50 60 
AGGTGGCCGGCTATGTCCTCATTGCCCTCAACACCGTGGAGAGAATCCCTTT«3AGAACCTGCAGATCATCAGGGGAAATGCTCTTTATGAAAACAC^ 
V A G Y V L I A L N T V E R I P L E N L Q I I R G N A L Y E N T Y A L A I L S N Y G T N R T G L R E 
7 0 80 90 1 0 0 1 1 0 
AACTGCCCATCCGGAACTTACAGGAAATCCTGATTGGTGCTGTGCGATTCAGCAACAACCCCATCCTCTGCAATATGGATACTATCCAGTGGAGGGACAT^ 
b P M R N L Q E I L I G A V R F S N N P I L C N M D T I Q W R D I V Q N V F M S N M S M D L Q S H P 
1 2 0 1 3 0 1 4 0 1 5 0 1 6 0 
CGAGCAGTTGCCCCAAATGTGATCCAAGCTGTCCCAATGGAAGCTGCTGGGGAGGAGGAGAGGAGAACTGCCAGAAATreACCAAAATCATCTXJTGCCCAGCAATGTrCC^ 
S S C P K C D P S C P N G S C W G G G E E N C Q K L T K I I C A Q Q C S H R C R G R S P S D C C H N 
1 7 0 1 8 0 1 9 0 2 0 0 2 1 0 
ACCAATGTGCTGCGGGGTGTACAGGGCCCCGAGAGAGTlGACTGTCrroGTCTGCCAAAAGTTCCAAGATEAGGCCACATGCAAAGACACCTGCXCACCACTC^^ 
Q C A A G C T G P R E S D C L V C Q K F Q D E A T C K D T C P P L M L Y N P T T Y Q M D V N P E G K 
2 2 0 2 3 0 2 4 0 2 5 0 2 6 0 
AGTACAGCTTTGGTGCCACCTGTGTGAAGAAGTGCCCCCGAAACTACGTGGTCACAGATCATXSGTrCATGTGTCaSAGCCTGTGGGCCTGACTACTACB^ 
Y S F G A T C V K K C P R N Y V V T D H G S C V R A C G P D Y Y E V E E D G I R K C K K C D G P C R 
2 7 0 2B0 2 9 0 3 0 0 3 1 0 
GCAAAGTTTGTAATGGCATAGGCATTGGTGAATTTAAAGACACACrrCTCCATAAATGCTACAAACATX:AAACACTTCAAATACTGCACTGCCATCAGCGGGGACCTTCACA 
K V C N G I G I G E P K D T L S I N A T N I K H F K Y C T A I S G D L H I L P V A F K G D S F T R T 
3 2 0 3 3 0 3 4 0 3 5 0 3 6 0 
CTCCTCCT^TAGACCCACGAGAACTAGAAATTCTAAAAACCGTAAAGGAAATAACAGGCTITTIlKTGATTCAGGCTroGCCTGATAACTGGACTGACCTCCAT^ 
P P L D P R E L E I L K T V K E I T G F L L I Q A W P D N W T D L H A P E N L E I I R G R T K Q H G 
3 7 0 3 8 0 3 9 0 4 0 0 4 1 0 
G'rcAGTTTTCTTTOGCGGTCG'ITGGCCT'SAACATCACATCACTGGGGCTGCCnTCCCTCAAGGAGATCAGTGATWSGGATG 
C F S L A V V G L N I T S L G L R S L K E I S D G D V I I S G N R N L C Y A N T I N W K K L F G T P 
4 2 0 4 3 0 4 4 0 4 5 0 4 6 0 
CCAATCAGAAAACCAAAATCATCAACAACAGAGCTGAGAAAGACTGCAAGGCXXTGAACCACGTCTGCAATCCTTrATCCTCCTCGGAAGG(^ 
N Q K T K I H N N R A E K D C K A V N H V C N P L C S S E G C W G P E P R D C V S C Q N V S R G R E 
4 7 0 4 8 0 4 9 0 5 0 0 5 1 0 
A G T G C G T G G A G A A A T G C A A C A T C C T G G A G G G G G A A C C A A G G G A G T T T G T G G A A A A T T C T G A A T G C A T C C A G T G C C A T C X ; A G A A T G T C T G C C C C A G G C X : A T G A A C A T ^ 
C V E K C N I L E G E P R E F V E N S E C I Q C H P E C L P Q A M N I T C T G R G P D N C I Q C A H 
5 2 0 5 3 0 5 4 0 6 5 0 5 6 0 
ACTACATTOATGGCCCAC^CTGTGTCAAGACCTSCCCAGCTGGCATC^TGGGAGAGAACAACACTCTGGTCTGGAAGTATGCAGATGCCAATAATGTCTGCCAC^ 
Y I D G P H C V K T C P A G I M G E N N T L V W K Y A D A N N V C H L C H A N C T Y G C A G P G L Q 
5 7 0 5 8 0 5 9 0 6 0 0 6 1 0 
AAGGATGTGAAGT3TGGCX;ATCTGGGCa^AAGATACCATCTATTGCCACTGGGATIX?reGGTGGCCTCCTCTIX:ATAGTGGTGGTGGCCC^^ 
G C E V W P S G P K I P S l A T G I V G G L L F I V V V A L G I G L F M R R R H I V R K R T L R R L 
6 2 0 6 3 0 6 4 0 6 5 0 6 6 0 
TGCTTCAAGAGAGAGAGCTCGTGGAACCTCTCACACCCAGCGGAGAAGCTCCAAACCAAGCCCACTTGAGGATATTAAAGGAAACAGAATTCAAAAAGATCAAAGTTCTGGGT^ 
L Q E R E L V E P L T P S G E A P N Q A H L R I L K E T E P K K I K V L G S G A F G T V Y K G L W I 
6 7 0 6 8 0 6 9 0 • • 7 0 0 7 1 0 
TCCCAGAAGGTGAGAAAGTAAAAATCCX:GGTGGCCAT:AAGGAGTrAAGAGAAGCCACATCTa:AAAAGCCAACAAAGAAATCCTTGACG7LAGCCTATGTGATGGCTAGTGT^ 
P E G E K V K I P V A I K E L R E A T S P K A N K E I L D E A Yl V IM A S V D N P H V C R L L G I C L 
7 2 0 • 7 3 0 7 4 0 | G | 7 5 0 7 6 0 
TGACCTCCACTGT::CAGCTCATTACACAGCTCATGCCOTACGGTTCCCTCCTrKACTACGTCCGAGAACACAAGGACAACATTCGCTCCCAGTAC^ 
T S T V Q L I T Q L M P Y G C L L D Y V R E H K D N I G S Q Y L L N K C V C I A K S M N Y L E D R R 
7 7 0 7 8 0 7 9 0 8 0 0 8 1 0 
GTITGGTGCACCGTGACTIO3CAGCXAGGAATGTACTXX;TGAAGACACCACAGCATGTCAAGATCACAGATTITGGGCrG0CCAAACTCCTTGGTC 
L V H R D L A A R N V L V K T P Q H V K I T D F G L A K L L G A E E K E Y H A E G G K V P I K W M A 
8 2 0 8 3 0 8 4 0 8 5 0 8 6 0 
ClTrGGAATCAATrrrACACCGAATTrATACACACX:AAAGTGAT(rrCTGGAGCrATGGT(rK:ACTGTC7I\WGAACTGATGACCTTra^ 
L E S I L H R I Y T H Q S D V W S Y G V T V W E L M T F G S K P Y D G I P A S D I S S I L E K G E R 
8 7 0 8 8 0 8 9 0 9 0 0 9 1 0 
GCCTTCCACAGCCACCTATCTGCACCATCGATGTCTACATCATCATGGTCAAGTGCTGGATGATAGATGCTGATAGCCGCCCAAAGTTCCGAGAGTTGAT^ 
L P Q P P I C T I D V Y M I M V K C W M I D A D S R P K F R E L I L E P S Q M A R D P Q R Y L V I Q 
9 2 0 9 3 0 - ^ 9 4 0 9 5 0 9 6 0 
AGGGGGATGAAAGAATGCATTTGCCAAGCCCTACAGACTCCAACriTTACCGAGCCCTGATGGATGAAGAGGACATGGAGGATGTAGTrGATGCTGATGAGTATCTTAT^ 
G D E R M H L P S P T D S N F Y R A L M D E E D M E D V V D A D E Y L I P Q Q G F F N S P S T S R T 
9 7 0 9 8 0 9 9 0 1 0 0 0 l O l O 
CTCCCCTCTTXJAGTTCTCTGAGTGCAACTAGCAACAATrCCACTGTGGCTTGCATTAATAGAAATGGGAGCTGCCGTTrrcAAAGAAGACGCCTK^^ 
P L L S S L S A T S N N S T V A C I N R N G S C R V K E D A F L Q R Y S S D P T G A V T E D N I D D 
1 0 2 0 1 0 3 0 1 0 4 0 1 0 5 0 1 0 6 0 
ACGCATTCCTCCCTGTACCTGAATATGTAAACCAATCTGTrcrcAAGAGGCCAGCAGGCTCTGTGCAGAACCCTGTCTATCACAATCAG 
A F L P V P E Y V N Q S V P K R P A G S V Q N P V Y H N Q P L H P A P G R D L H Y Q N P H S N A V G 
1 0 7 0 1 0 8 0 1 0 9 0 1 1 0 0 1 1 1 0 
GCAACCCTXSAGTATCTCAACACroccCAGCCTACCTGTCTCAGTAGTGGGTTTAACAGCCCTGCACTCTGGATCCAGAAAGGCAGTCACCAAATGAGCCTAGACAACC^ 
N P E Y L N T A Q P T C L S S G F N S P A L W I Q K G S H Q M S L D N P D y Q Q D F F P K E T K P N 
1 1 2 0 1 1 3 0 1 1 4 0 1 1 5 0 1 1 6 0 
ATGGCATATTTAAGGGCCCCACAGCTGAAAATGCAGAGTACCTACGGGTGGCACCTCCAAGCAGTGAGTTTATTGGAOCATGAcaagaaggggcatcataccag 3 6 5 4 
G I F K G P T A E N A E Y L R V A P P S S E F I G A * 
1 1 7 0 1 1 8 0 
Figure 7. Sequence comparison of normal and wa-2 murine EGFR cDNAs. Overlapping 
EGFR cDNAs were generated by reverse transcription and PCR amplification of total 
liver RNAs isolated from B6C3 (+ / +) and wa-2 ( - / - ) mice, and subjected to auto-
mated dideoxy nucleotide sequence analysis. [A] Deduced nucleotide and predicted 
amino acid sequence of the normal murine EGFR. Nucleotides are numbered from the 
first position of the initiating methionine, amino acids from the first residue following 
the predicted signal peptide. The transmembrane domain is underlined, arrowheads 
denote the boimdaries of the tyrosine kinase domain homology as defined by Hanks et 
al. (1988), and the dot marks the position of a residue analogous to lysine 721 in the 
ATP-binding site of the human EGFR that is essential for tyrosine kinase activity. The 
amino acid substitution in the wa-2 EGFR is boxed, and the arrow points to the mutated 
nucleotide. Note that this sequence will appear in the EMBL, GenBank, and DDBJ 
nucleotide sequence data bases vmder accession number U03425. (B) A manual dideoxy 
sequencing gel comparing wild-type and •wa-2 cDNAs in the region of the mutation 
(arrows). Asterisks indicate the predicted amino acid difference. 
control wa-2 
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Table 1. Comparison of subdomain III sequences in various 
tyrosine kinases 
Tyrosine 
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.. EKEALMSELK 
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. .MPEAFLQEAQ 


















M A S V .. . 
MAGV . . . 
MASM 
MA S E . . . 
MKGF . . . 
MKE F . . . 
MSNF . . . 
LTML . . . 
MKD F . . . 
MSHL . . . 
MSHL . . . 
L S Y L . . . 
MKKL . . . 
MKKL . . 
MKKL . . 
MKOL .. 
Subdomain HI sequences from conserved tyrosine kinase do-
mains are from Hanks et al. (1988). An invariant glutamic acid 
(E) residue is in boldface type; and the position of hydrophobic 
residues (valine-V, isoleucine-I, leucine-L) corresponding to the 
valine that is mutated in wa-2 mice is boxed. The subdomain III 
sequence shovsrn for EGFR is completely conserved between the 
human, mouse, rat, and chicken species. 
ent cultures (60-mm dishes) of the Chinese hamster 
ovary (CHO) cell line were transiently transfected (lipo-
fectamine; GIBCO/BRL) with 3 |xg of either the parental 
vector or constructs encoding the chimeric wild-type or 
wa-2 receptors. This particular cell line was chosen be-
cause it normally lacks detectable EGFR. Transfected 
cells were serum starved for 2 hr and, 24 hr after trans-
fection, exposed to varying doses of exogenous EGF for 2 
min. Cells were then lysed, and equivalent amounts of 
protein immimoprecipitated with the rabbit anti-EGFR 
antibody. Resulting complexes were resolved on SDS~-
PAGE and immunoblotted with anti-phosphotyrosine 
antibody. As shown in Figure 8, phosphotyrosine-cen-
taining proteins of —170 and 160 kD were readily de-
tected in samples from cells transfected with the wild-
type EGFR construct but not the parental vector. Be-
cause both species were detected in parallel blots probed 
with anti-EGFR antibody (Fig. 8, bottom), we presume 
that the broad 170-kD band corresponds to fully glyco-
sylated EGFR, whereas the more defined 160-kD species 
represents the biosynthetic precursor of the mature re-
ceptor, an intracellular form that contains core oligosac-
charides added during or shortly after its translation 
(Soderquist and Carpenter 1984; Mayes and Waterfield 
1984). This form acquires the ability to bind ligand prior 
to full maturation to the 170-kD form (Slicker and Lane 
1985). Note that consistent with this description, the 
phosphotyrosine content of the 170-kD receptor is mod-
estly enhanced in response to increasing concentrations 
of EGF, whereas that of the 160-kD species is unchanged. 
In samples from cells transfected with EGFR containing 
the wa-2 mutation, on the other hand, only the 170-kD 
phosphotyrosine-containing protein was observed. 
Whereas the phosphotyrosine content of this protein was 
more obviously enhanced in response to EGF, the abso-
lute level of phosphotyrosine was markedly reduced at 
every EGF concentration relative to that of the wild-type 
receptor. Densitometric analysis of the 170-kD EGFR in 
Figure 8 revealed the ratio of wild-type to wa-2 autophos-
phorylation to be —14-, 4-, and 3-fold at EGF concentra-
tions of 10, 30, and 100 ng/ml, respectively. This differ-
ence in apparent phosphotyrosine content was not at-
tributable to variations in the level of EGFR protein as 
shown by a parallel blot with anti-EGFR antibody (Fig. 8, 
bottom). Similar results were obtained in a separate ex-
periment in which cells were transfected with 0.6 |xg of 
EGFR cDNAs, serum starved for 18 hr, and harvested at 
48 hr (data not shown). The discrepancy between the 
activation of the wild-type and wa-2 receptors was also 
observed following calcium phosphate transfection of 
CHO cells (data not shown). We interpret these collec-
tive results to indicate that the tyrosine kinase of the 
wild-type receptor is fully active and only marginally 
ligand-dependent because of a relatively high concentra-
tion of receptors in the transfected cells. This robust ac-
tivity leads to ligand-independent transphosphorylation 
of the nascent, 160-kD receptor in intracellular compart-
ments. In contrast, the tyrosine kinase activity of recep-
tor containing the wa-2 mutation is markedly impaired 
and is unable to self-activate in intracellular compart-
ments even when overexpressed. However, the surface 
wa-2 receptor retains the ability to be partially stimu-
lated by ligand. 
control +/+EGFR wa-2 EGFR 
nr 
EGF(ng/ml): o 5 > « ? ^ o 5 > ' ? . 9 o . S > « ? 5 > 
p-tyr MUMS 
M 
»-• mm -170 
EGFR 
Jj^H ^^jjk M^k j^/jt ^ ^ ^ ^ ^ ^^Mk J^^t^ - 1 7 0 
Figure 8. Comparison of wild-type and wa-2 EGFR activities 
in transfected cells. Subcontinent (50-80%) CHO cells were li-
pofected with 3 |xg samples of parental pcDNAS (control), or 
pcDNAS containing wild-type ( + /+ EGFR) or wa-2 EGFR 
cDNAs. At 22 hr post-transfection, cells were serum starved for 
2 hr and then incubated with the indicated concentrations of 
EGF for 2 min. Cells were then lysed, and equivalent samples of 
protein (500 |xg) immunoprecipitated with a rabbit anti-EGFR 
antiserum (anti-ERCT). Immunoprecipitates were subjected to 
reducing SDS-PAGE and Western blotting with anti-phospho-
tyrosine antibody [top] or EGFR [bottom] antiserum. An arrow 
marks the position of the nascent, 160-kD receptor. 
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Discussion 
In this report we have estabhshed the basis of the mouse 
wa-2 phenotype to be impaired tyrosine kinase activity 
of EGFR, and we have shown that this defect is the result 
of a mutation within the amino-terminal portion of the 
tyrosine kinase domain. Although the wa-2 mutation 
does not inactivate the tyrosine kinase, it does reduce its 
activity by 80-95% compared with that of control levels. 
The finding that such reductions are associated with 
skin and eye abnormalities (Keeler 1935; Butler and Rob-
ertson 1953) similar to those of mice containing dis-
rupted TGF-a genes (Luetteke et al. 1993; Maim et al. 
1993) confirms a requirement for signaling by this 
ligand/receptor pair in the normal development and 
functioning of these tissues. Our results point to one of 
the few examples in which a necessary interaction be-
tween a ligand and its receptor has been established. An-
other is provided by the corequirement for the steel fac-
tor and its receptor c-Kit, as mutations in either simi-
larly produce mice with abnormalities in neural-crest 
derivatives, hematopoietic stem cells, and germ cells 
(Russell 1979). 
EGFR transcripts and/or protein are detected, albeit in 
varying levels, in most tissues. Expression of the numer-
ous EGF family ligands (EGF, TGF-a, amphiregulin, HB-
EGF, and betacellulin) is also collectively widespread. It 
is perhaps surprising, therefore, that phenotypes associ-
ated with reduced EGFR signaling capacity are, as in the 
case of TGF-a deficiency, restricted to skin and (variably) 
eyes. With TGF-a deficiency, this limited phenotype was 
conjectured to be the result of functional redundancy, 
possibly reflecting the presence in other contexts of ad-
ditional EGFR ligand family members. Although other 
EGFR-related proteins have been identified, including 
Her2/ErbB2/Neu (Bargmaim et al. 1986), Her3/ErbB3 
(Kraus et al. 1989; Plowman et al. 1990), and Her4/ErbB4 
(Plowman et al. 1993), none of these related proteins 
have been shown to bind EGF family ligands. The latter 
observation suggests that if functional redundancy ac-
coimts for the restriction in phenotype in wa-2 mice, it 
must be accounted for by other ligand/receptor systems. 
Altematively, because the wa-2 mutation does not com-
pletely inactivate the EGFR kinase, it is also possible 
that skin and eyes are particularly vulnerable to pertur-
bations in the activity of this signaling system. We ob-
served the level of EGF-induced phosphorylation in wa-2 
mice to be most conspicuously and consistently reduced 
in skin (see Fig. 6B,C). Because the relevant EGFR activ-
ity (vis-a-vis the wa-2 defect) is presumably localized to 
hair follicles and, hence, represents only a portion of the 
activity assayed in skin homogenates, signaling in the 
affected compartment could be even more impaired rel-
ative to other tissues. Finally, consistent with an en-
hanced sensitivity of skin or hair follicles, it should also 
be noted that a number of distinct mutations have been 
shown to influence the texture of mouse fur (Trigg 1972; 
Lyon and Searle 1989). 
The wa-2 defect provides the first example of a natu-
rally occurring EGFR mutation. To our knowledge, va-
line 743 (residue 741 in the human EGFR) has not been 
specifically and deliberately mutated, although deletion 
of amino acids immediately following it have been 
shown to inactivate the tyrosine kinase (Segatto et al. 
1991). Additionally, a 10-amino-acid insertion just 
downstream of the ATP-binding domain of v-ErbB re-
sulted in temperature-sensitive transforming and pro-
tein-tyrosine kinase activities (Ng and Privalsky 1986). 
And, reminiscient of our own results, a 4-amino-acid in-
sertion at residue 708 of the human protein abolished 
tyrosine kinase activity of the immunoprecipitated re-
ceptor but not its ability to stimulate ligand-dependent 
DNA synthesis (Prywes et al. 1986). Valine 743 is con-
served in human, mouse and rat EGFRs, as well as in 
Her2/ErbB2/Neu, and it is conservatively replaced by an 
isoleucine in Her4/ErbB4. It is also either conserved or 
conservatively replaced by leucine or isoleucine in a 
large number of both receptor and nomreceptor tyrosine 
kinases (Hanks et al. 1988; Table 1). The latter observa-
tion suggests that the placement of a hydrophobic amino 
acid at this relative position is critical, possibly because 
of its influence on local secondary and tertiary struc-
tures. That the substitution of a glycine at this position 
could have a detrimental effect is supported by the find-
ing that the transforming potential of Ras can be acti-
vated as a result of the converse change, that is, the sub-
stitution of a valine for a glycine residue at position 12 of 
the Ras protein that is associated with a local, though 
critical, conformational change (Wittinghofer and Pai 
1991). Additionally, the activity of chicken EGFR is 
stimulated by the deliberate replacement of an isoleu-
cine for an invariant valine residue (position 702 in hu-
man EGFR) within the ATP-binding pocket (Shu et al. 
1990). How the glycine for valine substitution impairs 
the wa-2 EGFR kinase is presently imclear, though its 
proximity to lysine 723 (lysine 721 in human EGFR) 
raises the possibility that the mutation could exert its 
effect by compromising ATP binding. 
Reduced tyrosine kinase activity could affect EGFR 
signaling through a number of distinct mechanisms. For 
example, cytoplasmic sequences have been implicated 
previously in the appearance of high, but not low, affin-
ity EGF-binding sites on the cell surface, and some mu-
tations that abolish tyrosine kinase activity (e.g., a 
4-amino-acid insertion at residue 888) also prevented ex-
pression of the high affinity state (Prywes et al. 1986). 
However, it should be noted that we did not observe 
major differences in the apparent binding affinities of 
normal and wa-2 EGFRs. Another possibility is that the 
wa-2 mutation depresses receptor oligomerization that 
appears to be necessary for kinase activation (Schless-
inger 1988). Altematively, the wa-2 mutation could in-
fluence EGFR trafficking. Thus, certain tyrosine kinase-
inactivating mutations, including the aforementioned 
residue 888 insertion (Prywes et al. 1986), also prevented 
EGFR down-regulation (Chen et al. 1987; Glenney et al. 
1988), and the specific mutation of lysine 721 in the 
ATP-binding pocket altered cellular routing of EGFR 
such that internalized receptors were recycled to the cell 
surface (Honegger et al. 1987,1990). Although mutations 
408 GENES & DEVELOPMENT 
 Cold Spring Harbor Laboratory Press on February 2, 2021 - Published by genesdev.cshlp.orgDownloaded from 
wa-2 encodes a defective EGF receptoi 
that effectively block EGFR down-regulation might gen-
erally be expected to enhance receptor signaling, the pos-
sibility exists that less drastic mutations (e.g., like that 
of wa-2) might influence EGFR routing in a manner that 
is detrimental to normal signaling, for example, by re-
pressing a normal level of receptor recycling. 
In addition to the preceding considerations, the wa-2 
mutation could directly impact signaling pathways as a 
consequence of deficient tyrosine phosphorylation of the 
EGFR and physiologically relevant substrates. Kinetic 
analyses have demonstrated that EGFR autophosphory-
lation relieves a competitive inhibitory constraint on ac-
tivity of the kinase toward exogenous substrates, per-
haps through a conformational change (Bertics et al. 
1985; Honegger et al. 1988). Furthermore, several key 
effector molecules in the mitogenic signal transduction 
pathway have been shown to preferentially associate 
with autophosphorylated receptor via interaction be-
tween their SH2 domains and the phosphotyrosines in 
the EGFR carboxyl terminus (Koch et al. 1991; Carpenter 
1992). For example, receptor tyrosine kinase activity has 
been shown to be essential for its association with phos-
pholipase C--y (PLC-'y) (Margolis et al. 1990), and efficient 
PLC--y phosphorylation is dependent on the presence of 
its SH2 domains (Rotin et al. 1992). In addition, GRB2, 
though apparently not a substrate of the EGFR tyrosine 
kinase, associates with phosphorylated receptors (Lo-
wenstein et al. 1992) serving as an SH2 adaptor protein in 
a ternary complex with Son of sevenless (SOS) that stim-
ulates ras activity (Buday and Downward 1993; Chardin 
et al. 1993; Egan et al. 1993; Gale et al. 1993; Li et al. 
1993; Rozakis-Adcock et al. 1993). Another SH2 domain-
containing protein, SHC, associates with and is phospho-
rylated by EGFR in cultured cells (Pelicci et al. 1992) and 
neonatal mouse tissues (Ruff-Jamison et al. 1993) ex-
posed to EGF. Furthermore, SHC also associates with 
GRB2 (Rozakis-Adcock 1992). We detected a similar 55-
kD protein in our phosphotyrosine Western blots of neo-
natal mouse tissues, and the phosphorylation of this pro-
tein was depressed in wa-2 skin. Thus, the defective ty-
rosine kinase activity of the wa-2 receptor could impinge 
on several signaling pathways, possibly producing tissue-
specific effects if association with key substrate(s) is 
preferentially perturbed in skin or hair follicles. Finally, 
it is interesting to note that the impact of the wa-2 mu-
tation appeared greater when assayed in vitro than in 
vivo. Although the basis of this difference is presently 
imclear, it suggests that receptor phosphorylation or sig-
nal transduction is also modulated by extrinsic factors in 
addition to the receptor's own intrinsic tyrosine kinase 
activity. In this regard, it is interesting to note that a 
kinase-negative EGFR was shown recently to activate 
MAP kinase and imdergo a low level of phosphorylation, 
possibly through an associated protein kinase activity 
(Campos-Gonzalez and Gleimey 1992; Selva et al. 1993). 
Furthermore, cross talk between EGFR and other recep-
tor signaling systems could dampen the effect of the 
wa-2 mutat ion in vivo (Kokai et al. 1988). 
Nimierous reports describe the sensitivity of skin and 
hair to exogenous EGFR ligands (Moore et al. 1983; Tam 
1985; Barrandon and Green 1987; Vassar and Fuchs 
1991). Our demonstration that EGFR transcripts are lo-
calized to the outer root sheath of hair follicles is con-
sistent with a previous assay of receptor protein (Green 
et al. 1984; King et al. 1990). Together with our recent 
findings (Luetteke et al. 1993), the present results further 
support the hypothesis that hair growth is, in part, con-
trolled by interactions between EGFR and TGF-a. The 
limited range of these interactions raises the possibility 
that they could be mediated by the membrane-bound 
TGF-a precursor (pro-TGF-a) rather than soluble forms. 
Development of follicles and elongation of the hair shaft 
are believed to be dependent on coordinated proliferation 
and migration of the inner and outer root sheaths (Straile 
1962; Hardy 1992). Disruptions in this coordinated func-
tion as a result of impaired EGFR signaling could pro-
duce hairs with irregular caliber and cell deposition 
(McLaren 1971). Finally, it is also possible that defective 
receptor signaling alters keratinization (Cheng et al. 
1993) within the follicle or the shaft itself. Future studies 
should be aimed at imderstanding the role of EGFR sig-
naling in this complex and dynamic system. 
Materials and methods 
Animals 
Mice harboring the wa-2 mutation (B6C3-Si/A-vt/vt-wa-2/wa-
2) and mice of the appropriate background strain (B6C3HF1) 
were obtained from The Jackson Laboratory (Bar Harbor, ME). 
Pieparation of membranes 
The livers of adult males were Dounce homogenized in STE 
buffer [250 mM sucrose, 10 mM Tris-HCl (pH 7.4), 2 mM EGTA] 
with protease inhibitors (1 mM PMSF, 20 jjig/ml of leupeptin, 20 
p.g/ml of aprotinin) and the homogenates centrifuged at 10,000g 
for 30 min. To collect microsomal membranes, supematants 
were centrifuged at 100,000g for 1 hr, and pellets resuspended in 
1 ml of 10 mM Tris-HCl (pH 7.4), 0.15 M NaCl, and aliquots 
frozen at -70°C. For enrichment of plasma membranes, the 
10,000g pellet was rehomogenized in STE and centrifuged in a 
PercoU gradient as described (Nakamura et al. 1983). After ex-
tensive washing, the plasma membrane fractions were ali-
quoted and stored at - 70°C. Total protein content was deter-
mined with the enhanced BCA assay (Pierce, Rockford IL). 
EGFR autophosphorylation 
Samples of freshly thawed microsomal membranes (50 fig pro-
tein) were incubated for 1 hr on ice with designated concentra-
tions of murine EGF (GIBCO BRL) in 40 |xl of 50 mM PIPES (pH 
7.0), 30 mM MgCl2. Autophosphorylation was initiated by the 
addition of 10 jtl of (-/-̂ ^PJATP (0.5 M-Ci/ml) in 5 JJLM ATP. After 
1 min on ice (unless specified otherwise), reactions were 
stopped with 50 |xl of 2x SDS-PAGE sample buffer, and proteins 
resolved on 7% denaturing SDS-polyacrylamide gels. Gels were 
fixed in 10% isopropanol and 10% acetic acid and dried for 
autoradiography. Where indicated, dried gels were rehydrated, 
heated at 55°C for 2 hr in 1 M KOH to preferentially remove 
serine/threonine phosphorylation, and fixed and dried for auto-
radiography. In some experiments, autophosphorylation was 
performed with solubilized membranes in the presence of 0.1% 
Triton X-100, after 1 hr incubation at room temperature with 
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ligand or antibody. In others, we observed that the level of either 
wild-type or wa-2 EGFR autophosphorylation was not signifi-
cantly different when membranes were incubated in the pres-
ence of 200 |jiM vanadate. 
Tyrosine kinase assay 
Aliquots (100 |xl) of freshly thawed liver microsomal mem-
branes were solubilized on ice in 1% Triton X-100/10% glyc-
erol, diluted to 1 ml with immvmoprecipitation (IP) buffer [50 
mM HEPES (pH 7.5), 0.15 mM NaCl, 1 mM EDTA, 1% Triton 
X-100, 10% glycerol, 1 mM PMSF, 20 ftg/ml of leupeptin, 0.1 
TlU/ml of aprotininj and incubated for 2 hr on ice with either 
10 nl of preimmime rabbit serum or 1382 rabbit antiserum that 
recognizes the external domain of EGFR. Immune complexes 
were precipitated with 20 (il of 50% (vol/vol) Staph A cells 
(Pansorbin, Calbiochem) for 2 hr at 4°C, washed once with IP 
buffer, and washed twice and resuspended with 2x tyrosine 
kinase buffer [100 mM HEPES (pH 7.6), 60 mM MgClj, 4 mM 
MnCli, 0.2% NP-40, 400 M,M Nag VO4). Immunoprecipitates 
(from 300 |xg of original membrane protein) were incubated for 
15 min at 25°C with 2 mg/ml of poly-Glu acid or poly-(Glu/ 
Na,Tyr; 4:1) or poly-(Glu, Ala, Tyr; 6:3:1) (Sigma) in 80 p.! of 1 x 
tyrosine kinase buffer containing 0.5% Triton X-100 and 5.0 
|xCi [7-^^P]ATP in 10 |XMATP. Reactions were microcentrifuged 
for 1 min to pellet the immimoprecipitates, and 50 ^1 of super-
natant spotted onto Whatman 3MM filter paper squares. The 
filter papers were washed for 30 min each in 10% trichloroace-
tic acid (TCA), 10 mM sodimn pyrophosphate, and two changes 
of 5% TCA, dried overnight, and covmted in liquid scintillation 
cocktail. 
In vivo phosphorylation 
Control (-I- / - ) and wavy-haired mutant ( - / - ) pups (7-8 days 
old) of similar weight were injected subcutaneously in the neck 
with 20-30 |xl of phosphate-buffered saline (PBS) or indicated 
amounts of EGF in PBS. Ten minutes later, mice were sacrificed 
and tissues harvested and homogenized as described previously 
(Donaldson and Cohen 1992). Protein concentrations in centri-
fuged tissue homogenates were determined with a Coomassie 
blue dye-binding assay (Bio-Rad). Equivalent amoimts of protein 
were resolved by denaturing 7% SDS-PAGE, transferred to Im-
mobilon-P (Millipore), and subjected to immvmoblotting with 
rabbit anti-ERCT (raised against a glutathione-S-transferase pro-
tein containing the carboxy-terminal-most 100 amino acids of 
rat EGFR; 1:1000 dilution) or with monoclonal antibody to 
phosphotyrosine (1:10,000 dilution of PY-20 coupled to horse-
radish peroxidase, ICN), followed by chemiluminescent detec-
tion (ECL, Amersham). Where indicated, neonatal tissue ho-
mogenates were immunoprecipitated with the EGFR antiserum 
and protein A-Sepharose (Pharmacia) prior to SDS-PAGE and 
immunoblotting. 
Nucleic acid analyses 
Total RNA was isolated and subjected to Northern analysis as 
described previously (Han et al. 1987). Two overlapping 2-kb 
cDNAs corresponding roughly to the extracellular and intracel-
lular domains of the EGF receptor were generated by reverse 
transcription of 1 p,g total liver RNAs and subsequent PCR am-
plification (Luetteke et al. 1993). The first primer pair amplified 
from nucleotide position —149 to position -1-1857, 85 bp up-
stream from the transmembrane domain: 5'-TACCGCCTC-
CCAGACAGACGA-3' (forward) and 5'-TAGGTGGCAGA-
CATTATTGGCATC-3' (reverse). The second primer pair am-
plified from position 1580 to position 3697, 65 bp downstream 
of the stop codon: 5'-AGAATGTGAGCAGAGGCAGGGA-3' 
(forward) and 5'-CTGCCATGGCTTGGTCCTGGG-3' (re-
verse). PCR was performed for 30 cycles of 1 min each at 94°C, 
1 min at 60°C, and 3 min at 72°C. Products were resolved on 1% 
agarose gels, and the cDNAs isolated (GeneClean, Bio 101) and 
subcloned into the pCR n vector (TA cloning kit, Invitrogen). 
These mouse cDNAs were used as probes in the Northern and 
in situ hybridizations (Sandgren et al. 1993). The nucleic acid 
sequence of the cloned products was determined by the UNC-
CH Automated DNA Sequencing Facility using Applied Biosys-
tems. Inc., instrumentation. Manual sequencing was performed 
with the Sequenase version 2.0 kit (U.S. Biochemical). 
Cell Transfections 
CHO cells were obtained from the American Tissue Culture 
Collection (ATCC) and grown in Dulbecco's minimal essential 
medium (DMEM) supplemented with nonessential amino acids 
and 10% fetal bovine serum (FBS). Cells in 60-mm dishes at 
50-80% confluency were transfected with 18 id of lipo-
fectamine (GIBCO/BRL) and 3 p,g of EGFR constructs as rec-
ommended by the manvifacturer. 
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